Hydroxychloroquine Through Every Trimester: A Guide for Autoimmune Patients Planning Pregnancy

When Maya, a 31-year-old teacher from outside Chicago, was diagnosed with systemic lupus erythematosus at age 26, her first question to her rheumatologist was not about her treatment plan. It was about her future children. "I needed to know," she recalled, "whether having a baby was even something I could safely do—and whether the medication I was taking would be part of that picture."

Maya's concern is one shared by hundreds of thousands of American women of childbearing age who live with lupus, rheumatoid arthritis, Sjögren's syndrome, and other systemic autoimmune conditions. For many of them, hydroxychloroquine (Plaquenil) is a daily constant—a medication they have taken for years to manage inflammation, prevent organ damage, and maintain quality of life. The prospect of pregnancy raises an urgent and deeply personal question: is it safe to continue?

The answer, according to a growing body of evidence and the guidance of leading rheumatology organizations, is not only that it is generally safe—but that stopping hydroxychloroquine during pregnancy may actually carry greater risks than continuing it.

Understanding the Stakes: Autoimmune Disease and Pregnancy

Pregnancy is an immunologically complex state. For women without autoimmune disease, the immune system undergoes carefully orchestrated shifts to tolerate the developing fetus. For women with conditions like lupus, however, pregnancy can trigger disease flares, increase the risk of complications such as preeclampsia and preterm birth, and place both mother and baby at elevated risk.

Lupus in particular is associated with a heightened likelihood of pregnancy loss, intrauterine growth restriction, and neonatal lupus—a condition in which maternal antibodies cross the placenta and temporarily affect the newborn's heart and skin. Managing maternal disease activity before and during pregnancy is therefore not merely a matter of maternal comfort; it is a direct determinant of fetal outcomes.

This is the clinical context in which hydroxychloroquine's role in pregnancy must be evaluated.

What the Evidence Actually Shows

Hydroxychloroquine has been studied in pregnant women with autoimmune conditions for more than three decades. The accumulated data are remarkably consistent.

A landmark study published in Arthritis & Rheumatism found that lupus patients who discontinued hydroxychloroquine during pregnancy experienced significantly higher rates of disease flares than those who continued therapy. Subsequent research confirmed and expanded these findings, with multiple cohort studies demonstrating that women who maintained their Plaquenil regimen through pregnancy had:

• Fewer lupus flares during gestation and the postpartum period
• Lower rates of preeclampsia
• Reduced risk of preterm delivery in some analyses
• Improved neonatal outcomes, including lower incidence of neonatal lupus manifestations in at-risk pregnancies

The American College of Rheumatology's reproductive health guidelines explicitly recommend that hydroxychloroquine be continued throughout pregnancy in women with lupus and other autoimmune conditions for which it is indicated. This recommendation is echoed by the European League Against Rheumatism (EULAR) and the British Society for Rheumatology.

Critically, decades of pregnancy exposure data have not identified a pattern of fetal harm attributable to hydroxychloroquine. The drug does cross the placenta, but it has not been associated with increased rates of birth defects, miscarriage, or developmental abnormalities in human studies.

The Preconception Window: Planning Ahead Matters

For women considering pregnancy, the months before conception are arguably the most important period in the entire reproductive journey. Rheumatologists and maternal-fetal medicine specialists consistently advise that disease activity be well-controlled for at least three to six months before attempting conception. This window allows providers to:

• Assess the safety of all current medications (some DMARDs and immunosuppressants must be discontinued prior to conception)
• Optimize hydroxychloroquine dosing
• Screen for antiphospholipid antibodies and anti-Ro/SSA and anti-La/SSB antibodies, which carry specific pregnancy risks
• Establish a coordinated care team including rheumatology, obstetrics, and maternal-fetal medicine

Women who arrive at pregnancy already on a stable, well-tolerated hydroxychloroquine regimen are in a significantly stronger position than those who attempt to manage a flare mid-pregnancy with limited medication options.

Real Voices: What Patients Experience

"My rheumatologist told me early on that stopping Plaquenil would be riskier than staying on it," said Diane, a 34-year-old mother of two from Atlanta who has managed RA since her late twenties. "That was counterintuitive to me at first—I assumed pregnancy meant a clean slate, no medications. But she walked me through the research, and it changed my perspective completely. Both of my pregnancies went smoothly, and I never had a major flare."

Not every patient's story unfolds without complexity. Some women experience mild disease activity despite continued therapy; others require careful dose adjustments or the addition of pregnancy-compatible agents like low-dose aspirin or low-molecular-weight heparin for specific risk profiles. The key, patients and clinicians agree, is that these decisions are made proactively and collaboratively—not reactively in the middle of a flare.

Breastfeeding: Continuing the Conversation Postpartum

The postpartum period presents its own set of concerns. Autoimmune disease flares are common in the weeks following delivery, as the immune system recalibrates after the immunologic shifts of pregnancy. For women who wish to breastfeed, the question of whether hydroxychloroquine passes into breast milk—and whether that poses a risk to the infant—is a natural concern.

Studies measuring hydroxychloroquine concentrations in breast milk have found that the amounts transferred to nursing infants are very small—well below levels considered pharmacologically significant. Both the ACR and the Infantrisk Center at Texas Tech University Health Sciences Center classify hydroxychloroquine as compatible with breastfeeding. Women are encouraged to discuss this with their rheumatologist and pediatrician, but the existing evidence supports continuation of therapy during lactation.

Neonatal Lupus: What Parents Should Know

For women who carry anti-Ro/SSA or anti-La/SSB antibodies—a subset of lupus and Sjögren's patients—there is a specific risk of neonatal lupus, most seriously manifesting as congenital heart block. Hydroxychloroquine has been studied as a potential preventive strategy in this population, with some evidence suggesting that maternal use may reduce the recurrence risk of cardiac neonatal lupus in subsequent pregnancies. While this remains an area of active investigation, the signal is encouraging and further supports the case for continuing therapy in high-risk pregnancies.

Building Your Care Team

Navigating pregnancy with an autoimmune condition is not a journey any patient should undertake without a well-coordinated medical team. The ideal care structure typically includes:

• A rheumatologist experienced in managing autoimmune disease during pregnancy
• A maternal-fetal medicine (MFM) specialist or high-risk obstetrician
• A pediatric cardiologist, for women with anti-Ro/SSA antibodies
• A pharmacist familiar with reproductive safety data for autoimmune medications

At PlaquenilRx Shop, we understand that accessing the right medications is only one part of a larger picture. For patients managing autoimmune conditions through some of life's most significant transitions, reliable information and trusted clinical partnerships are equally essential. If you are planning a pregnancy or have recently received an autoimmune diagnosis and have questions about your long-term treatment options, we encourage you to consult your rheumatologist—and to come to that conversation equipped with the knowledge that continuing hydroxychloroquine through pregnancy is, for many women, not a risk to be weighed but a protection to be embraced.